619 related articles for article (PubMed ID: 20804223)
1. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
Orofino J; Soto J; Casado MA; Oyagüez I
Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
[TBL] [Abstract][Full Text] [Related]
2. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
3. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
Schey C; Milanova T; Hutchings A
Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
[TBL] [Abstract][Full Text] [Related]
4. Patient Access to Medicines for Rare Diseases in European Countries.
Detiček A; Locatelli I; Kos M
Value Health; 2018 May; 21(5):553-560. PubMed ID: 29753352
[TBL] [Abstract][Full Text] [Related]
5. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
6. Determinants of orphan drugs prices in France: a regression analysis.
Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
[TBL] [Abstract][Full Text] [Related]
8. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
9. Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes DA; Tunnage B; Yeo ST
QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
[TBL] [Abstract][Full Text] [Related]
10. Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe.
Medic G; Korchagina D; Young KE; Toumi M; Postma MJ; Wille M; Hemels M
J Mark Access Health Policy; 2017; 5(1):1299665. PubMed ID: 28473888
[No Abstract] [Full Text] [Related]
11. Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases.
Schlander M; Dintsios CM; Gandjour A
Value Health; 2018 May; 21(5):525-531. PubMed ID: 29753348
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of orphan drug prices in Europe.
Young KE; Soussi I; Hemels M; Toumi M
J Mark Access Health Policy; 2017; 5(1):1297886. PubMed ID: 28473887
[No Abstract] [Full Text] [Related]
13. Penetration rates of new pharmaceutical products in Europe: A comparative study of several classes recently launched in type-2 diabetes.
Le Pen C; Bauduceau B; Ansolabehere X; Troubat A; Bineau S; Ripert M; Dejager S
Ann Endocrinol (Paris); 2021 Apr; 82(2):99-106. PubMed ID: 33417963
[TBL] [Abstract][Full Text] [Related]
14. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
15. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
16. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists.
Clegg JP; Guest JF; Lehman A; Smith AF
Ophthalmic Epidemiol; 2006 Aug; 13(4):263-74. PubMed ID: 16877285
[TBL] [Abstract][Full Text] [Related]
17. Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union.
Żelewski P; Wojna M; Sygit K; Cipora E; Gąska I; Niemiec M; Kaczmarski M; Banaś T; Karakiewicz B; Kotwas A; Zabielska P; Partyka O; Pajewska M; Krzych-Fałta E; Bandurska E; Ciećko W; Czerw A
Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231399
[TBL] [Abstract][Full Text] [Related]
18. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.
Ray JA; Valentine WJ; Secnik K; Oglesby AK; Cordony A; Gordois A; Davey P; Palmer AJ
Curr Med Res Opin; 2005 Oct; 21(10):1617-29. PubMed ID: 16238902
[TBL] [Abstract][Full Text] [Related]
19. The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change.
Young KE; Soussi I; Toumi M
J Mark Access Health Policy; 2017; 5(1):1369817. PubMed ID: 29081920
[No Abstract] [Full Text] [Related]
20. Impact of orphan drugs on Latvian budget.
Logviss K; Krievins D; Purvina S
Orphanet J Rare Dis; 2016 May; 11(1):59. PubMed ID: 27169704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]